Prof. Dr. Nizameddin KOCA | AVESİS

Akademik Veri Yönetim Sistemi

Yayınlar & Eserler

Makaleler 35

1. The role of lipid-derived indices in patients with MASLD in Turkey: a nationwide, multicenter cross-sectional study

SOLMAZ İ., Kırık A., DEMİR İ., DİZDAR O. S., Gözel N., TAZEGÜL G., et al.

Scientific Reports , cilt.16, sa.1, 2026 (SCI-Expanded, Scopus)

Creative Commons License

2. Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception

KOCA N., UYAR S., ŞAHİNTÜRK Y., Yıldız H., Del Prato S., DeFronzo R.

Cardiovascular Diabetology , cilt.25, sa.1, 2026 (SCI-Expanded, Scopus)

3. Consumption-like Thrombocytopenia Phenotype Predicts ICU Mortality with Particular Relevance in Patients with Malignancy: A Retrospective Single-Center Cohort Study of 2188 Patients

Güllü Koca T., Hunutlu F. Ç., Ertınmaz A., Yanık A. M., Bilen Y., KOCA N.

Journal of Clinical Medicine , cilt.15, sa.12, 2026 (SCI-Expanded, Scopus)

4. Hidden Burden of Hypertension in Türkiye: A Multi-Center DAHUDER World Hypertension Day Study Reveals Gaps in Awareness, Adherence, and Control

SÜMBÜL H. E., SOLMAZ İ., Arac E., DEMİR İ., UYAR S., KONUR K., et al.

Journal of Clinical Medicine , cilt.15, sa.9, 2026 (SCI-Expanded, Scopus)

5. Uncoupling Systemic Inflammation from Body Mass Index: The Unseen Role of Visceral Adiposity and Metabolic Phenotypes—A Subgroup Analysis of the Nationwide OBREDI-TR Cohort

İşsever K., Oral A., Genç A. C., SOLMAZ İ., KOCA N., Topaloglu U. S., et al.

Journal of Clinical Medicine , cilt.15, sa.10, 2026 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

Sürdürülebilir Kalkınma

6. Discordance Between FIB-4 and BAST Fibrosis Risk Classifications in Obese Patients with MASLD: Results from the OBREDI-TR Study

Kama Basci O., Oral A., Kirik A., Sen H., SOLMAZ İ., Topaloglu U. S., et al.

Diagnostics , cilt.16, sa.4, 2026 (SCI-Expanded, Scopus)

7. Hepatic fibrosis severity assessed by FIB-4 index is independently associated with reduced kidney function in patients with metabolic dysfunction-associated steatotic liver disease: a nationwide multicenter study from Türkiye

SÜMBÜL H. E., Kirik A., Yaylaci S., Oral A., Serin S. O., Issever K., et al.

Hepatology International , 2026 (SCI-Expanded, Scopus)

8. Beyond awareness: analyzing the incomplete integration and barriers to POCUS implementation: a nationwide study

TAZEGÜL G., GÜVEN A. T., Serin S. O., Yalçın N., IRMAK KAYA Z., KONUR K., et al.

Internal and Emergency Medicine , 2026 (SCI-Expanded, Scopus)

9. Calcium to magnesium ratio as a superior biomarker for nephrolithiasis detection in primary hyperparathyroidism

Yalçın N., Ertınmaz Özkan A., GÜNEŞ E., KOCA N.

Scientific Reports , cilt.15, sa.1, 2025 (SCI-Expanded, Scopus)

Creative Commons License

10. Adjunctive pancreatin therapy enhances glycemic and metabolic outcomes in type 2 diabetes mellitus: the modifying role of exocrine pancreatic function

KOCA N., Yalçın N.

Diabetes Research and Clinical Practice , cilt.229, 2025 (SCI-Expanded, Scopus)

11. Neuromedin U and BMI correlation in T1DM and T2DM vs healthy controls: A comparative study

Çalışkan Y., SARANDÖL E., KOCA N.

Endocrinologia, Diabetes y Nutricion , cilt.72, sa.8, 2025 (Scopus)

12. Prevalence of MASLD and Fibrosis Risk in Turkish Adults with Cardiometabolic Risk Factors: A Nationwide Multicenter Study (DAHUDER MASLD Study)

Kirik A., SÜMBÜL H. E., KOCA N., PAŞALI KİLİT T., Demiral Sezer S., Binnetoglu E., et al.

Journal of Clinical Medicine , cilt.14, sa.19, 2025 (SCI-Expanded, Scopus)

Creative Commons License

13. Real-World Impact of SGLT2 Inhibitors on Systemic Inflammation in Type 2 Diabetes: A Composite Biomarker-Based Evaluation

Yalçın N., KOCA N.

Sakarya Medical Journal , cilt.15, sa.3, ss.280-287, 2025 (Scopus, TRDizin)

Creative Commons License

14. Effectiveness and hepatic safety of short-term low-dose tolvaptan for severe hyponatremia: A retrospective comparative study

UYAR S., Kaplan Çayir M., KOCA N.

Medicine (United States) , cilt.104, sa.33, 2025 (SCI-Expanded, Scopus)

15. Impact of SGLT2 Inhibitors on Cardiovascular Risk Scores, Metabolic Parameters, and Laboratory Profiles in Type 2 Diabetes

Yalçın N., AKTAŞ S., UYAR S., KOCA N.

Life , cilt.15, sa.5, 2025 (SCI-Expanded, Scopus)

Creative Commons License

16. Obesity-Related Disorders in Türkiye: A Multi Center, Retrospective, Cross-Sectional Analysis from the OBREDI-TR Study

Oral A., SOLMAZ İ., KOCA N., Topaloglu U. S., DEMİR İ., Dundar A., et al.

Journal of Clinical Medicine , cilt.14, sa.8, 2025 (SCI-Expanded, Scopus)

Creative Commons License

17. Impact of Comorbid Polycystic Ovary Syndrome on Clinical and Laboratory Parameters in Female Adolescents with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Study

Keskin M., Arsoy H. A., KARA Ö., SARANDÖL E., KOCA N., YILMAZ Y.

Journal of Clinical Medicine , cilt.13, sa.19, 2024 (SCI-Expanded, Scopus)

18. The evaluation of the short-term and long-term hydroxychloroquine therapy on ECG parameters

UYAR S., Kök M., Ayan A., COŞKUNER M. A., KÖKER G., KOCA N.

Medicine (United States) , cilt.103, sa.32, 2024 (SCI-Expanded, Scopus)

19. Metabolic Dysfu nctio n-As socia ted Fatty Liver Disease and Fibrosis Status in Patients with Type 2 Diabetes Treated at Internal Medicine Clinics: Türkiye DAHUDER Awareness of Fatty Liver Disease (TR-DAFLD) Study

ŞAHİNTÜRK Y., KÖKER G., KOCA N., SÜMBÜL H. E., DEMİR İ., KESKİN H., et al.

Turkish Journal of Gastroenterology , cilt.36, sa.8, ss.643-650, 2024 (SCI-Expanded, Scopus, TRDizin)

20. The association of Neuromedin U levels and non-alcoholic fatty liver disease: A comparative analysis

Keskin M., Avul S., Beyaz A., KOCA N.

Heliyon , cilt.10, sa.5, 2024 (SCI-Expanded, Scopus)

21. Assessment of nutritional status and clinical outcomes: A comprehensive retrospective analysis of critically ill patients

Özkan A. E., KOCA N., Tekeli A. H.

Medicine (United States) , cilt.102, sa.44, 2023 (SCI-Expanded, Scopus)

22. Effects of disease-modifying therapies on lipid parameters in patients with multiple sclerosis

KOCA N., Seferoğlu M.

Multiple Sclerosis and Related Disorders , cilt.77, 2023 (SCI-Expanded, Scopus)

23. Evaluation of EfficientNet models for COVID-19 detection using lung parenchyma

Kurt Z., IŞIK Ş., KAYA Z., ANAGÜN Y., KOCA N., Çiçek S.

Neural Computing and Applications , cilt.35, sa.16, ss.12121-12132, 2023 (SCI-Expanded, Scopus)

24. Impact of Smoking on Disease Severity and Mortality of Hospitalized Patients with Confirmed COVID-19

Güllü Y. T., Kulucan E., Tuna N. T., Köksal N., KOCA N.

Addicta: the Turkish Journal on Addictions , cilt.9, sa.2, ss.121-125, 2022 (Scopus, TRDizin)

25. COVID-19 Disease in Kidney Transplant Recipients Enfermedad por COVID-19 en receptores de trasplante renal

Simsek A., KOCA N.

Revista de Nefrologia, Dialisis y Trasplante , cilt.42, sa.3, ss.181-188, 2022 (SCI-Expanded, Scopus)

26. The Impact of Early Phase COVID-19 Vaccination on Hospitalized COVID-19 Patients

Güllü Y. T., Kulucan E., Tuna N. T., Köksal N., KOCA N.

Tohoku Journal of Experimental Medicine , cilt.257, sa.2, ss.147-151, 2022 (SCI-Expanded, Scopus)

Creative Commons License

27. Estimated glomerular filtration rate in identifying illness severity in newly admitted patients with COVID-19: A single-center study

ÜSTÜNDAĞ Y., Engindeniz F. T., HUYSAL K., Kologlu R. F., ASAN A., KOCA N., et al.

International Journal of Medical Biochemistry , cilt.5, sa.1, ss.44-48, 2022 (Scopus, TRDizin)

28. Can diabetes insipidus be used as a marker for multisystemic and progressive disease in Langerhans cell histiocytosis?

KOCA N., CANDER S., ÖZ GÜL Ö.

Kuwait Medical Journal , cilt.53, sa.4, ss.453-457, 2021 (SCI-Expanded, Scopus)

29. The evaluation of the role of BMi and insulin resistance on inflammatory markers, PAI-1 levels and arterial stiffness in newly diagnosed type 2 diabetes mellitus patients

KOCA N., AYAR K., BAL Ö., ERSOY C.

Minerva Endocrinology , cilt.46, sa.1, ss.116-123, 2021 (SCI-Expanded, Scopus)

30. Evaluation of retinal vascularization by optical coherence tomography angiography (OCTA) in rheumatoid arthritis, and its relationship with disease activity

AYAR K., Can M. E., KOCA N., Çelik D. Ş.

Modern Rheumatology , cilt.31, sa.4, ss.817-826, 2021 (SCI-Expanded, Scopus)

31. Optical coherence tomography angiography findings in axial spondylarthritis

KOCA N., AYAR K., Can M. E.

Rheumatology International , cilt.40, sa.6, ss.901-913, 2020 (SCI-Expanded, Scopus)

32. Food Addiction Correlates with Psychosocial Functioning More Than Metabolic Parameters in Patients with Obesity

KÜÇÜKSARAÇ KIYICI D. S., KOCA N., SIĞIRLI D., Aslan B. B., Guclu M., KISAKOL G.

Metabolic Syndrome and Related Disorders , cilt.18, sa.3, ss.161-167, 2020 (SCI-Expanded, Scopus)

33. Insulinoma case admitted with reactive hypoglycemia symptoms

KOCA N., CANDER S., ÖZ GÜL Ö., UĞRAŞ N.

Current Diabetes Reviews , cilt.16, sa.7, ss.790-796, 2020 (ESCI, Scopus)

34. The association between cardiac valvular calcification and fetuin-A levels in kidney transplant recipients

KOCA N., ERSOY A., Şensoy B., Kırhan E., Güllülü S., ERSOY C., et al.

Clinical and Experimental Nephrology , cilt.23, sa.10, ss.1250-1256, 2019 (SCI-Expanded, Scopus)

35. Physical activity, insulin sensitivity, and metabolic control in type 1 diabetes mellitus Tip 1 diabetes mellitusta fiziksel aktivite, İnsülin duyarliliği ve metabolik kontrol

KOCA N., Güçlü M., Esen I., Emlek G., KÜÇÜKSARAÇ KIYICI D. S., KISAKOL G.

Turkish Journal of Endocrinology and Metabolism , cilt.23, sa.1, ss.8-18, 2019 (Scopus, TRDizin)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 1

1. Deep Learning-Based COVID-19 Detection Using Lung Parenchyma CT Scans

KAYA Z., Kurt Z., IŞIK Ş., KOCA N., Çiçek S.

International Conference on Computing and Communication Networks, ICCCN 2021, Virtual, Online, 19 - 20 Kasım 2021, cilt.394, ss.261-275, (Tam Metin Bildiri)

Metrikler

Yayın

36

Yayın (WoS)

33

Yayın (Scopus)

36

H-İndeks (WoS)

8

Atıf (Scopus)

166

H-İndeks (Scopus)

8

Atıf (TrDizin)

3

H-İndeks (TrDizin)

1

Atıf (Diğer Toplam)

3

Tez Danışmanlığı

7

Açık Erişim

14

BM Sürdürülebilir Kalkınma Amaçları

SDG 3: AMAÇ 3: SAĞLIKLI BİREYLER